Asalyxa Bio develops nano-engineered, immune cell-targeted therapeutics built on its proprietary PANTHER technology platform. The PANTHER platform enables targeted delivery of therapeutic compounds directly to neutrophils and other key immune cells, and can deliver existing and novel drugs. Its lead program, ASX-100, is a neutrophil-targeted formulation being developed for the resolution of Acute Respiratory Distress Syndrome (ARDS). Proceeds from the recent seed financing will be used to advance ASX-100 into first-in-human clinical trials. The company is led by president and CEO Marc Appel and is advancing drug-development programs across multiple disease areas driven by dysregulated immune signaling.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2021